A 38-year-old woman from Delhi presents to the dermatology clinic with complaints of progressive darkening and velvety thickening of skin over her neck, armpits, and inner thighs for the past 2 years. She is obese (BMI 34 kg/m²), has irregular menstrual cycles, and reports difficulty conceiving. On examination, she has hirsutism and acanthosis nigricans with well-demarcated hyperpigmented plaques. Fasting blood glucose is 115 mg/dL, insulin level is 28 mIU/mL (normal <12), and pelvic ultrasound shows multiple small cysts in both ovaries. What is the most appropriate first-line management for her skin condition?

Explanation

## Management of Benign (Metabolic) Acanthosis Nigricans ### Clinical Diagnosis This patient has **benign acanthosis nigricans** secondary to: 1. **Insulin resistance** (elevated fasting insulin with normal glucose) 2. **Polycystic ovary syndrome (PCOS)** (irregular cycles, hirsutism, polycystic ovaries) 3. **Obesity** (BMI 34 kg/m²) **Key Point:** The *gradual onset over 2 years* with metabolic features (obesity, PCOS, hyperinsulinemia) and *absence of constitutional symptoms* or malignancy distinguish this from paraneoplastic AN. ### Pathophysiology of Benign AN **High-Yield:** Insulin resistance → hyperinsulinemia → activation of insulin-like growth factor-1 receptor (IGF-1R) on keratinocytes and melanocytes → epidermal thickening and melanin deposition. **Mnemonic:** **IRIS** — Insulin Resistance, IGF-1 signaling, Receptor activation, Skin thickening ### Management Algorithm ```mermaid flowchart TD A[Benign Acanthosis Nigricans]:::outcome --> B{Underlying cause?}:::decision B -->|Insulin resistance + obesity| C[Weight reduction target 5-10%]:::action B -->|PCOS| D[Metformin 1500-2000 mg/day]:::action B -->|T2DM| E[Optimize glycemic control]:::action C --> F[Improved insulin sensitivity]:::outcome D --> F E --> F F --> G[AN regresses over 6-12 months]:::outcome H[Topical agents + sunscreen]:::action -.->|Adjunctive| G ``` ### First-Line Interventions (In Order of Efficacy) | Intervention | Mechanism | Timeline | Evidence | |---|---|---|---| | **Weight reduction (5–10%)** | ↓ Insulin resistance, ↑ insulin sensitivity | 6–12 months | Strong; AN regresses proportional to weight loss | | **Metformin 1500–2000 mg/day** | ↓ Hepatic glucose production, ↑ insulin sensitivity | 3–6 months | Moderate; especially in PCOS | | **Glycemic control** (if T2DM) | ↓ Hyperglycemia-driven EGFR signaling | 3–6 months | Strong | | **Topical agents** (hydroquinone, tretinoin) | Melanin inhibition, keratinocyte turnover | 2–3 months | Weak; cosmetic only, does not address root cause | **Clinical Pearl:** AN is a **marker of insulin resistance**, not a primary dermatologic disease. Treating the skin without addressing insulin resistance leads to treatment failure and cosmetic disappointment. ### Why Weight Reduction is Superior - **Addresses root cause**: Insulin resistance - **Improves fertility**: Weight loss restores ovulation in PCOS - **Reduces cardiovascular risk**: Metabolic syndrome management - **Durable response**: AN regresses as insulin sensitivity improves ### Expected Timeline - **3 months**: Fasting insulin and HOMA-IR improve - **6 months**: Visible lightening of AN, improved skin texture - **12 months**: Near-complete resolution in responders **Warning:** Topical depigmenting agents alone (option 2) provide only cosmetic cover and do not reverse the underlying pathology. Retinoids (option 0) and corticosteroids (option 3) are not indicated for benign AN.